16/05/2026 ImPact Biotech’s padeliporfin VTP delivers 70% complete response with durable safety in Phase 3 LG‑UTUC, setting up 2027 regulatory submission and expansion into solid tumors ImPact Biotech’s padeliporfin VTP delivers 70% complete response with durable safety in Phase 3 LG‑UTUC, setting up 2027 regulatory submission and expansion into solid tumors (Ref) Biotech’s updated Phase 3 ENLIGHTED trial data for padeliporfin VTP in low‑grade upper tract urothelial carcinoma